Literature DB >> 27043833

Emergency Care of Patients with Acute Ischemic Stroke in the Kaiser Permanente Southern California Integrated Health System.

Kori Sauser-Zachrison1, Ernest Shen2, Zahra Ajani3, William P Neil4, Navdeep Sangha5, Michael K Gould6, Adam L Sharp7.   

Abstract

CONTEXT: Tissue plasminogen activator (tPA) is underutilized for treatment of acute ischemic stroke.
OBJECTIVE: To determine whether the probability of tPA administration for patients with ischemic stroke in an integrated health care system improved from 2009 to 2013, and to identify predictors of tPA administration.
DESIGN: Retrospective analysis of all ischemic stroke presentations to 14 Emergency Departments between 2009 and 2013. A generalized linear mixed-effects model identified patient and hospital predictors of tPA. MAIN OUTCOME MEASURES: Primary outcome was tPA administration; secondary outcomes were door-to-imaging and door-to-needle times and tPA-related bleeding complications.
RESULTS: Of the 11,630 patients, 3.9% received tPA. The likelihood of tPA administration increased with presentation in 2012 and 2013 (odds ratio [OR] = 1.75; 95% confidence interval [CI] = 1.26-2.43; and OR = 2.58; 95% CI = 1.90-3.51), female sex (OR = 1.27; 95% CI = 1.04-1.54), and ambulance arrival (OR = 2.17; 95% CI = 1.76-2.67), and decreased with prior stroke (OR = 0.47; 95% CI = 0.25-0.89) and increased age (OR = 0.98; 95% CI = 0.97-0.99). Likelihood varied by Medical Center (pseudo-intraclass correlation coefficient 13.5%). Among tPA-treated patients, median door-to-imaging time was 15 minutes (interquartile range, 9-23 minutes), and door-to-needle time was 73 minutes (interquartile range, 55-103 minutes). The rate of intracranial hemorrhage was 4.2% and 0.9% among tPA- and non-tPA treated patients (p < 0.001).
CONCLUSION: Acute ischemic stroke care improved over time in this integrated health system. Better understanding of differences in hospital performance will have important quality-improvement and policy implications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27043833      PMCID: PMC4867819          DOI: 10.7812/TPP/15-124

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  14 in total

1.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

Authors:  I L Katzan; A J Furlan; L E Lloyd; J I Frank; D L Harper; J A Hinchey; J P Hammel; A Qu; C A Sila
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

2.  Predictors of rapid brain imaging in acute stroke: analysis of the Get With the Guidelines-Stroke program.

Authors:  Adam G Kelly; Anne S Hellkamp; Daiwai Olson; Eric E Smith; Lee H Schwamm
Journal:  Stroke       Date:  2012-03-22       Impact factor: 7.914

3.  Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.

Authors:  Irene L Katzan; Maxim D Hammer; Anthony J Furlan; Eric D Hixson; Deborah M Nadzam
Journal:  Stroke       Date:  2003-02-13       Impact factor: 7.914

4.  Intravenous thrombolysis for stroke increases over time at primary stroke centers.

Authors:  Shyam Prabhakaran; Maggie McNulty; Kathleen O'Neill; Bichun Ouyang
Journal:  Stroke       Date:  2011-12-01       Impact factor: 7.914

5.  Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001.

Authors:  Adnan I Qureshi; M Fareed K Suri; Abu Nasar; Wei He; Jawad F Kirmani; Afshin A Divani; Charles J Prestigiacomo; Ronald B Low
Journal:  Neurosurgery       Date:  2005-10       Impact factor: 4.654

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

8.  Time to brain imaging in acute stroke is improving: secondary analysis of the INSTINCT trial.

Authors:  Kori Sauser; James F Burke; Deborah A Levine; Phillip A Scott; William J Meurer
Journal:  Stroke       Date:  2013-11-14       Impact factor: 7.914

9.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.

Authors:  Irene L Katzan; Maxim D Hammer; Eric D Hixson; Anthony J Furlan; Alex Abou-Chebl; Deborah M Nadzam
Journal:  Arch Neurol       Date:  2004-03

10.  Joint commission primary stroke centers utilize more rt-PA in the nationwide inpatient sample.

Authors:  Michael T Mullen; Scott E Kasner; Michael J Kallan; Dawn O Kleindorfer; Karen C Albright; Brendan G Carr
Journal:  J Am Heart Assoc       Date:  2013-03-26       Impact factor: 5.501

View more
  2 in total

1.  Safe and Effective Implementation of Telestroke in a US Community Hospital Setting.

Authors:  Kori Sauser-Zachrison; Ernest Shen; Navdeep Sangha; Zahra Ajani; William P Neil; Michael K Gould; Dustin Ballard; Adam L Sharp
Journal:  Perm J       Date:  2016-07-25

2.  Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients.

Authors:  Elyar Sadeghi-Hokmabadi; Mohammad Yazdchi; Mehdi Farhoudi; Homayoun Sadeghi; Aliakbar Taheraghdam; Reza Rikhtegar; Hannaneh Aliyar; Sahar Mohammadi-Fallah; Rogayyeh Asadi; Elham Mehdizadeh-Far; Neda Ghaemian
Journal:  Iran J Neurol       Date:  2018-01-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.